as 11-21-2024 4:00pm EST
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 10.2M | IPO Year: | 2016 |
Target Price: | $21.00 | AVG Volume (30 days): | 52.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.53 | EPS Growth: | N/A |
52 Week Low/High: | $0.60 - $4.88 | Next Earning Date: | 11-13-2024 |
Revenue: | $4,034,000 | Revenue Growth: | 166.27% |
Revenue Growth (this year): | 70.8% | Revenue Growth (next year): | 298.02% |
PAVM Breaking Stock News: Dive into PAVM Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
PR Newswire
3 days ago
Simply Wall St.
4 days ago
Thomson Reuters StreetEvents
7 days ago
GuruFocus.com
7 days ago
PR Newswire
7 days ago
PR Newswire
14 days ago
PR Newswire
16 days ago
The information presented on this page, "PAVM PAVmed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.